Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Bortezomib for Injection 3.5 mg/vial, approved by the U.S. Food and Drug Administration (USFDA) via a 505(b)(2) new drug application (NOA) pathway for intravenous use only.
"We're pleased to bring this product to market for the customers and patients who will benefit from this cost efficient alternative in the market place," explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories. "This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio of products in the Hospital segment."
Dr. Reddy's Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.2857.5 as compared to the previous close of Rs. 2870.55. The total number of shares traded during the day was 7136 in over 538 trades.
The stock hit an intraday high of Rs. 2887.8 and intraday low of 2854. The net turnover during the day was Rs. 20395577.